Bucladesine sodium

SKU: orb1308676

Description

Bucladesine sodium

Research Area

Metabolism Research, Signal Transduction

Key Properties

• CAS Number: 16980-89-5
• MW: 491.37
• Purity: 99.76%
• Formula: C₁₈H₂₃N₅NaO₈P
• SMILES: [NaH].CCCC(=O)Nc1ncnc2n(cnc12)[C@@H]1O[C@@H]2COP(O)(=O)O[C@H]2[C@H]1OC(=O)CCC
• Target: PDE,PKA
• Solubility: DMSO:144 mg/mL (293.06 mM);H2O:49.1 mg/mL (99.92 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (8.14 mM)

Bioactivity

• In Vivo:
  METHODS: To stud the anti-inflammatory activity in vivo Bucladesine sodium (0.24-0.7 µg/kg) was administered intraperitoneally to a mouse model of copper pine demyelination once daily for seven days. Results: Bucladesine had a Protective effect on myelin formation. Enhanced intracellular cAMP prevented demyelination and exerted anti-inflammatory and anti-apoptotic properties in a mouse model of copper pine demyelination. METHODS: To investigat the effects on liver injury, Bucladesine sodium (0.5-500 mg/kg) was intraperitoneally injected into C57BL/6J jcl mice, and liver injury was induced b the intravenous injection of rTNF-α (1.0 µg/kg) and intraperitoneal injection of D-gal (500 mg/kg) after 1 h the RESULTS showed that Bucladesine protected against hepatic injury in C57BL/6J jcl mice. Results: Bucladesine protected mice from TNF-α/D-gal-induced liver injury.Bucladesine significantly enhance the expression of Hsp70 in hepatocytes of D-gal/TNFα-injected mice, which was closely related to the Inhibition of liver injury.
• In Vitro:
  METHODS: Human eosinophil EoL-1 cells were treated with Bucladesine sodium (10-100 µM) for 8 days and activity was measured using PKA assay. Results: Proliferation of EoL-1 cells treated with Bucladesine sodium increased in a time-dependent manner. METHODS: PC12 cells were treated with Bucladesine sodium (1 mM for 72 h. TNF-α levels were measured by ELISA assay. Results: Bucladesine sodium increase the activity of PKA.
• Animal Research:
  Animal: Mice. Formulation: water/DMSO (9:1). Dosages: 600 nM. Administration: i.p.

Storage & Handling

• Storage: store at low temperature,keep away from moisture,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

inhibit, intracellular, lipophilic, Inhibitor, memory, ChAT, DC2797, DC-2797, DC 2797, dbcAMP, Dibutyryl cAMP, Dibutyryl-cAMP, Dibutyryl-cAMP sodium, Dibutyryl-cAMP sodium salt, anti-inflammatory, cAMP, CA1, Bucladesine, Bucladesine sodium, Bucladesine sodium salt, Sodium dibutyryl cAMP, spatial, Phosphodiesterase (PDE), phosphodiesterase, PKA, Protein kinase A, VAChT

Compound Identifiers

PubChem CID

154809571